HUE052444T2 - Makrociklusos polimorfok, kompozíciók, amelyek tartalmaznak ilyen polimorfokat és azok felhasználásának és elõállításának eljárásai - Google Patents

Makrociklusos polimorfok, kompozíciók, amelyek tartalmaznak ilyen polimorfokat és azok felhasználásának és elõállításának eljárásai

Info

Publication number
HUE052444T2
HUE052444T2 HUE18167730A HUE18167730A HUE052444T2 HU E052444 T2 HUE052444 T2 HU E052444T2 HU E18167730 A HUE18167730 A HU E18167730A HU E18167730 A HUE18167730 A HU E18167730A HU E052444 T2 HUE052444 T2 HU E052444T2
Authority
HU
Hungary
Prior art keywords
polymorphs
compositions
manufacture
methods
macrocyclic
Prior art date
Application number
HUE18167730A
Other languages
English (en)
Hungarian (hu)
Inventor
Yu-Hung Chiu
Tessie Che
Alex Romero
Yoshi Ichikawa
Youe-Kong Shue
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38661942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE052444(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of HUE052444T2 publication Critical patent/HUE052444T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
HUE18167730A 2007-01-22 2008-01-22 Makrociklusos polimorfok, kompozíciók, amelyek tartalmaznak ilyen polimorfokat és azok felhasználásának és elõállításának eljárásai HUE052444T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88195007P 2007-01-22 2007-01-22
US11/831,886 US7378508B2 (en) 2007-01-22 2007-07-31 Polymorphic crystalline forms of tiacumicin B

Publications (1)

Publication Number Publication Date
HUE052444T2 true HUE052444T2 (hu) 2021-05-28

Family

ID=38661942

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE18167730A HUE052444T2 (hu) 2007-01-22 2008-01-22 Makrociklusos polimorfok, kompozíciók, amelyek tartalmaznak ilyen polimorfokat és azok felhasználásának és elõállításának eljárásai
HUE08713185A HUE039395T2 (hu) 2007-01-22 2008-01-22 Makrociklikus polimorfok, kompozíciók, amelyek tartalmaznak ilyen polimorfokat, eljárások elõállításukra és felhasználásuk

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE08713185A HUE039395T2 (hu) 2007-01-22 2008-01-22 Makrociklikus polimorfok, kompozíciók, amelyek tartalmaznak ilyen polimorfokat, eljárások elõállításukra és felhasználásuk

Country Status (23)

Country Link
US (5) US7378508B2 (enExample)
EP (3) EP2468761A1 (enExample)
JP (2) JP5468388B2 (enExample)
KR (2) KR20150006082A (enExample)
CN (2) CN102746353A (enExample)
BR (1) BRPI0806878A2 (enExample)
CA (2) CA2880860A1 (enExample)
CY (1) CY1120358T1 (enExample)
DK (1) DK2125850T3 (enExample)
ES (2) ES2821384T3 (enExample)
HR (1) HRP20180912T1 (enExample)
HU (2) HUE052444T2 (enExample)
IL (2) IL199984A0 (enExample)
LT (1) LT2125850T (enExample)
MX (2) MX348083B (enExample)
NZ (2) NZ578697A (enExample)
PL (2) PL3412678T3 (enExample)
PT (2) PT2125850T (enExample)
RU (1) RU2478643C2 (enExample)
SI (1) SI2125850T1 (enExample)
TR (1) TR201810589T4 (enExample)
TW (2) TWI453015B (enExample)
WO (1) WO2008091554A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5113978B2 (ja) * 2003-11-21 2013-01-09 味の素株式会社 グルタミン酸誘導体の有機アミン塩及びその利用
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
ES2565609T3 (es) * 2004-05-14 2016-04-05 Merck Sharp & Dohme Corp. Tratamiento de enfermedades asociadas al uso de antibióticos
US7935377B2 (en) * 2004-06-04 2011-05-03 Ajinomoto Co., Inc. Crystals of free (2R, 4R)-monatin and use thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
MX2010000465A (es) * 2007-07-12 2010-08-30 Tragara Pharmaceuticals Inc Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
TWI523654B (zh) * 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
US9120815B2 (en) 2010-02-05 2015-09-01 Tragara Pharmaceuticals, Inc. Solid state forms of macrocyclic kinase inhibitors
CA2799531A1 (en) * 2010-05-18 2011-11-24 Optimer Pharmaceuticals, Inc. Treating recurring clostridium difficile infection using fidaxomicin
AU2012211968A1 (en) * 2011-02-04 2013-08-29 Optimer Pharmaceuticals, Inc. Treatment of bacterial infections
WO2013138748A1 (en) * 2012-03-16 2013-09-19 Optimer Pharmaceuticals, Inc. Prevention of clostridium difficile infection in high risk patients
US8722863B2 (en) 2012-05-10 2014-05-13 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof
WO2013170142A1 (en) 2012-05-10 2013-11-14 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof
JO3464B1 (ar) * 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
JP2016511268A (ja) 2013-03-08 2016-04-14 シプラ・リミテッド 直腸投与するための医薬組成物
CN103275152B (zh) * 2013-05-29 2015-11-18 华北制药集团新药研究开发有限责任公司 一种高纯度非达霉素的制备方法
CN103275153B (zh) * 2013-06-27 2016-03-23 华北制药集团新药研究开发有限责任公司 一种非达霉素晶体的制备方法
CN104560766B (zh) 2013-10-16 2017-07-28 浙江海正药业股份有限公司 一种游动放线菌菌株及其应用
US20150141356A1 (en) * 2013-11-15 2015-05-21 Optimer Pharmaceuticals, Inc. Treatment of Clostridium Difficile Infection in High Risk Patients
WO2015127955A1 (en) 2014-02-25 2015-09-03 Olon S.P.A. A new polymorph of tiacumicin b and process for preparation thereof
CA2940433A1 (en) 2014-02-25 2015-09-03 Olon S.P.A. Process for preparing novel forms of tiacumicin b
AU2015233583B2 (en) * 2014-03-18 2019-04-11 Xellia Pharmaceuticals Aps New polymorphs and new solid states of Tiacumicin B
WO2015169451A1 (en) 2014-05-09 2015-11-12 Astellas Pharma Europe Ltd Treatment regimen tiacumicin compound
US20150329582A1 (en) * 2014-05-13 2015-11-19 Jef DeBrabander Small molecule compounds selective against gram-negative bacterial infections
CN104098637B (zh) 2014-07-09 2017-01-04 浙江海正药业股份有限公司 一种纯化非达霉素的方法
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
JP2018519344A (ja) 2015-07-03 2018-07-19 アステラス ファーマ ユーロープ リミテッド チアクマイシン化合物の新規の投薬レジメン
CN112190589A (zh) * 2020-11-17 2021-01-08 首都医科大学附属北京胸科医院 非达霉素在制备抑制鸟分枝杆菌活性的产品中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1458512A (en) * 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US4321361A (en) * 1980-06-12 1982-03-23 Eli Lilly And Company Demycinosyltylosin and process for its production
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5583115A (en) 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
US5767096A (en) 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
JP2000072760A (ja) 1998-06-19 2000-03-07 Ajinomoto Co Inc 新規シストチアゾール類縁体
JP2000053514A (ja) 1998-08-06 2000-02-22 Aquas Corp レジオネラ属細菌が生産する殺菌性物質、これを用いた殺菌剤、水処理剤、スライム抑制剤、及びこれらの製造方法
JP2000239266A (ja) 1999-02-17 2000-09-05 Ajinomoto Co Inc 新規ポリエン系抗生物質
KR100832145B1 (ko) 2000-04-28 2008-05-27 코산 바이오사이언시즈, 인코포레이티드 폴리케타이드의 제조방법
WO2002032427A1 (en) 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
DK1539977T3 (en) * 2002-07-29 2014-11-17 Optimer Pharmaceuticals Inc PREPARATION OF TIACUMICIN
US20070105791A1 (en) 2002-07-29 2007-05-10 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
ES2565609T3 (es) 2004-05-14 2016-04-05 Merck Sharp & Dohme Corp. Tratamiento de enfermedades asociadas al uso de antibióticos
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
EP1848273A4 (en) * 2005-01-31 2010-02-24 Optimer Pharmaceuticals Inc 18-PIECE MACROCYCLES AND ITS ANALOG
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
CA2626698C (en) 2005-10-21 2015-12-01 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
US20080176927A1 (en) 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins
ZA200905337B (en) 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法

Also Published As

Publication number Publication date
CY1120358T1 (el) 2019-07-10
NZ578697A (en) 2012-08-31
KR20090117924A (ko) 2009-11-16
HUE039395T2 (hu) 2018-12-28
TWI453015B (zh) 2014-09-21
EP2468761A1 (en) 2012-06-27
PT2125850T (pt) 2018-07-11
TR201810589T4 (tr) 2018-08-27
NZ601347A (en) 2013-11-29
TW201350114A (zh) 2013-12-16
JP5764168B2 (ja) 2015-08-12
CA2676061A1 (en) 2008-07-31
SI2125850T1 (en) 2018-08-31
JP2010516681A (ja) 2010-05-20
EP3412678B1 (en) 2020-08-19
ES2821384T3 (es) 2021-04-26
LT2125850T (lt) 2018-08-10
HRP20180912T1 (hr) 2018-07-27
PL3412678T3 (pl) 2020-12-14
US8859510B2 (en) 2014-10-14
MX2009007730A (es) 2009-08-07
IL220255A0 (en) 2012-07-31
CN102746353A (zh) 2012-10-24
IL199984A0 (en) 2010-04-15
ES2676308T3 (es) 2018-07-18
RU2009131727A (ru) 2011-02-27
US7863249B2 (en) 2011-01-04
CN101663312B (zh) 2013-10-23
JP5468388B2 (ja) 2014-04-09
MX348083B (es) 2017-05-25
US7378508B2 (en) 2008-05-27
PT3412678T (pt) 2020-09-29
EP3412678A1 (en) 2018-12-12
WO2008091554A1 (en) 2008-07-31
EP2125850B1 (en) 2018-05-30
US20130252914A1 (en) 2013-09-26
US20090163428A1 (en) 2009-06-25
RU2478643C2 (ru) 2013-04-10
DK2125850T3 (en) 2018-07-30
EP2125850A1 (en) 2009-12-02
JP2013241440A (ja) 2013-12-05
US8883986B2 (en) 2014-11-11
PL2125850T3 (pl) 2018-08-31
CN101663312A (zh) 2010-03-03
US20070259949A1 (en) 2007-11-08
US20100081800A1 (en) 2010-04-01
AU2008209580A1 (en) 2008-07-31
TWI425942B (zh) 2014-02-11
KR20150006082A (ko) 2015-01-15
TW200840562A (en) 2008-10-16
CA2676061C (en) 2016-01-19
CA2880860A1 (en) 2008-07-31
BRPI0806878A2 (pt) 2014-06-24
US20080194497A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
PT2125850T (pt) Polimorfos macrocíclicos, composições que compreendem tais polimorfos, métodos de fabrico e utilização dos mesmos
HRP20190408T1 (hr) Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
HUS1900009I1 (hu) Új vegyületek és készítmények, továbbá alkalmazási eljárásaik
ZA200806842B (en) Imidazole-based compounds,compositions comprising them and methods of their use
ZA201308527B (en) Forms of rifaximin and uses thereof
PL3135720T3 (pl) Kompozycja środka porotwórczego z wodorochlorofluoroolefinową
EP1976675A4 (en) COMPOSITION, PREPARATION OF POLYCARBOSILANES AND THEIR USES
ZA200905337B (en) Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
ZA200905671B (en) Heterocyclic compounds, compositions comprising them and methods of their use
ZA201000992B (en) Anti-viral compounds, compositions, and methods of use
EP2340297A4 (en) COMPOSITION, ITS MANUFACTURING METHOD AND USE
IL205967A0 (en) Antibiotic macrocycle compounds and methods of manufacture and use thereof